allovax
Vaccineexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2013 (NCT01995227)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
Tumor antigens immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- allovax
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02624999 | Phase 2 | Dec 1, 2016 | Immunovative Therapies |
| NCT02409524 | Phase 2 | Jul 1, 2016 | Immunovative Therapies, National Cancer Institute (NCI) |
| NCT01995227 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2013 | Hebrew University, Immunovative Therapies |
| NCT01998542 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2013 | Immunovative Therapies |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immunovative Therapies | For profit | 4 | 4 | 1 | 2013 |
| Hebrew University | Academic/Hospital | 1 | 0 | 1 | 2013 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1